Literature DB >> 9774693

Direct interaction of Jak1 and v-Abl is required for v-Abl-induced activation of STATs and proliferation.

N N Danial1, J A Losman, T Lu, N Yip, K Krishnan, J Krolewski, S P Goff, J Y Wang, P B Rothman.   

Abstract

In Abelson murine leukemia virus (A-MuLV)-transformed cells, members of the Janus kinase (Jak) family of non-receptor tyrosine kinases and the signal transducers and activators of transcription (STAT) family of signaling proteins are constitutively activated. In these cells, the v-Abl oncoprotein and the Jak proteins physically associate. To define the molecular mechanism of constitutive Jak-STAT signaling in these cells, the functional significance of the v-Abl-Jak association was examined. Mapping the Jak1 interaction domain in v-Abl demonstrates that amino acids 858 to 1080 within the carboxyl-terminal region of v-Abl bind Jak1 through a direct interaction. A mutant of v-Abl lacking this region exhibits a significant defect in Jak1 binding in vivo, fails to activate Jak1 and STAT proteins, and does not support either the proliferation or the survival of BAF/3 cells in the absence of cytokine. Cells expressing this v-Abl mutant show extended latency and decreased frequency in generating tumors in nude mice. In addition, inducible expression of a kinase-inactive mutant of Jak1 protein inhibits the ability of v-Abl to activate STATs and to induce cytokine-independent proliferation, indicating that an active Jak1 is required for these v-Abl-induced signaling pathways in vivo. We propose that Jak1 is a mediator of v-Abl-induced STAT activation and v-Abl induced proliferation in BAF/3 cells, and may be important for efficient transformation of immature B cells by the v-abl oncogene.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9774693      PMCID: PMC109263          DOI: 10.1128/MCB.18.11.6795

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  56 in total

1.  Abl-interactor-1, a novel SH3 protein binding to the carboxy-terminal portion of the Abl protein, suppresses v-abl transforming activity.

Authors:  Y Shi; K Alin; S P Goff
Journal:  Genes Dev       Date:  1995-11-01       Impact factor: 11.361

2.  Abl protein-tyrosine kinase selects the Crk adapter as a substrate using SH3-binding sites.

Authors:  R Ren; Z S Ye; D Baltimore
Journal:  Genes Dev       Date:  1994-04-01       Impact factor: 11.361

3.  v-Abl-mediated apoptotic suppression is associated with SHC phosphorylation without concomitant mitogen-activated protein kinase activation.

Authors:  P J Owen-Lynch; A K Wong; A D Whetton
Journal:  J Biol Chem       Date:  1995-03-17       Impact factor: 5.157

4.  p210Bcr/Abl and p160v-Abl induce an increase in the tyrosine phosphorylation of p93c-Fes.

Authors:  T J Ernst; K E Slattery; J D Griffin
Journal:  J Biol Chem       Date:  1994-02-25       Impact factor: 5.157

Review 5.  Abl-mediated transformation, immunoglobulin gene rearrangements and arrest of B lymphocyte differentiation.

Authors:  N Rosenberg
Journal:  Semin Cancer Biol       Date:  1994-04       Impact factor: 15.707

6.  Jak-STAT signaling induced by the v-abl oncogene.

Authors:  N N Danial; A Pernis; P B Rothman
Journal:  Science       Date:  1995-09-29       Impact factor: 47.728

7.  c-Abl kinase regulates the protein binding activity of c-Crk.

Authors:  S M Feller; B Knudsen; H Hanafusa
Journal:  EMBO J       Date:  1994-05-15       Impact factor: 11.598

8.  Activation of a Drosophila Janus kinase (JAK) causes hematopoietic neoplasia and developmental defects.

Authors:  D A Harrison; R Binari; T S Nahreini; M Gilman; N Perrimon
Journal:  EMBO J       Date:  1995-06-15       Impact factor: 11.598

9.  Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the Bcr-Abl oncogene.

Authors:  C L Sawyers; J McLaughlin; O N Witte
Journal:  J Exp Med       Date:  1995-01-01       Impact factor: 14.307

10.  The COOH terminus of the c-Abl tyrosine kinase contains distinct F- and G-actin binding domains with bundling activity.

Authors:  R A Van Etten; P K Jackson; D Baltimore; M C Sanders; P T Matsudaira; P A Janmey
Journal:  J Cell Biol       Date:  1994-02       Impact factor: 10.539

View more
  16 in total

Review 1.  Stat transcription factors in mammary gland development and tumorigenesis.

Authors:  C J Watson
Journal:  J Mammary Gland Biol Neoplasia       Date:  2001-01       Impact factor: 2.673

2.  The carboxyl terminus of v-Abl protein can augment SH2 domain function.

Authors:  D Warren; A J Heilpern; K Berg; N Rosenberg
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

3.  p53 deficiency increases transformation by v-Abl and rescues the ability of a C-terminally truncated v-Abl mutant to induce pre-B lymphoma in vivo.

Authors:  X Zou; F Cong; M Coutts; G Cattoretti; S P Goff; K Calame
Journal:  Mol Cell Biol       Date:  2000-01       Impact factor: 4.272

4.  Jak/STAT pathways in cytokine signaling and myeloproliferative disorders: approaches for targeted therapies.

Authors:  Shashidhar S Jatiani; Stacey J Baker; Lewis R Silverman; E Premkumar Reddy
Journal:  Genes Cancer       Date:  2010-10

Review 5.  STAT signaling in the pathogenesis and treatment of cancer.

Authors:  D A Frank
Journal:  Mol Med       Date:  1999-07       Impact factor: 6.354

6.  The extreme carboxyl terminus of v-Abl is required for lymphoid cell transformation by Abelson virus.

Authors:  David Warren; Deborah S Griffin; Celine Mainville; Naomi Rosenberg
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

7.  Abl interactor 1 binds to sos and inhibits epidermal growth factor- and v-Abl-induced activation of extracellular signal-regulated kinases.

Authors:  P D Fan; S P Goff
Journal:  Mol Cell Biol       Date:  2000-10       Impact factor: 4.272

8.  Pim serine/threonine kinases regulate the stability of Socs-1 protein.

Authors:  X Peter Chen; Julie A Losman; Simone Cowan; Elizabeth Donahue; Scott Fay; Bao Q Vuong; Martijn C Nawijn; Danielle Capece; Victoria L Cohan; Paul Rothman
Journal:  Proc Natl Acad Sci U S A       Date:  2002-02-19       Impact factor: 11.205

9.  TYK2 is a key regulator of the surveillance of B lymphoid tumors.

Authors:  Dagmar Stoiber; Boris Kovacic; Christian Schuster; Carola Schellack; Marina Karaghiosoff; Rita Kreibich; Eva Weisz; Michaela Artwohl; Olaf C Kleine; Mathias Muller; Sabina Baumgartner-Parzer; Jacques Ghysdael; Michael Freissmuth; Veronika Sexl
Journal:  J Clin Invest       Date:  2004-12       Impact factor: 14.808

10.  NF-kappaB1 can inhibit v-Abl-induced lymphoid transformation by functioning as a negative regulator of cyclin D1 expression.

Authors:  Yukio Nakamura; Raelene J Grumont; Steve Gerondakis
Journal:  Mol Cell Biol       Date:  2002-08       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.